Published in Neurology on December 05, 2012
Clinical Profiles and Short-Term Outcomes of Acute Disseminated Encephalomyelitis in Adult Chinese Patients. J Clin Neurol (2016) 0.81
Health effects of lesion localization in multiple sclerosis: spatial registration and confounding adjustment. PLoS One (2014) 0.80
The impact of isolated lesions on white-matter fiber tracts in multiple sclerosis patients. Neuroimage Clin (2015) 0.79
Predicting outcome in clinically isolated syndrome using machine learning. Neuroimage Clin (2014) 0.78
Corpus callosum atrophy correlates with gray matter atrophy in patients with multiple sclerosis. J Neuroimaging (2014) 0.78
Predicting short-term conversion from CIS to MS: relevance of lesion distribution. Neurology (2012) 0.77
Increased cortical curvature reflects white matter atrophy in individual patients with early multiple sclerosis. Neuroimage Clin (2014) 0.76
Disease Activity and Conversion into Multiple Sclerosis after Optic Neuritis Is Treated with Erythropoietin. Int J Mol Sci (2016) 0.75
Fluctuations of spontaneous EEG topographies predict disease state in relapsing-remitting multiple sclerosis. Neuroimage Clin (2016) 0.75
A Novel Cervical Spinal Cord Window Preparation Allows for Two-Photon Imaging of T-Cell Interactions with the Cervical Spinal Cord Microvasculature during Experimental Autoimmune Encephalomyelitis. Front Immunol (2017) 0.75
MRI in the assessment and monitoring of multiple sclerosis: an update on best practice. Ther Adv Neurol Disord (2017) 0.75
Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage (2004) 49.54
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage (2006) 23.57
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage (2002) 8.03
Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med (2015) 6.96
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol (2013) 6.18
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med (2006) 5.20
Further Implications of Off-Label Use of Acetazolamide in the Management of Moyamoya Disease in Japan: Response. Radiology (2017) 4.99
Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS. Neurology (2013) 4.60
Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp (2005) 4.11
PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med (2013) 4.02
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet (2008) 3.93
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet (2011) 3.76
A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med (2002) 3.74
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol (2007) 3.47
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol (2009) 3.42
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med (2012) 3.16
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol (2011) 3.16
Functional-anatomical validation and individual variation of diffusion tractography-based segmentation of the human thalamus. Cereb Cortex (2004) 3.03
Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology (2013) 2.77
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol (2011) 2.75
Chronic cerebrospinal venous insufficiency and multiple sclerosis. Ann Neurol (2010) 2.63
Small vessel disease and general cognitive function in nondisabled elderly: the LADIS study. Stroke (2005) 2.59
Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke (2008) 2.57
Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol (2014) 2.51
Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology (2005) 2.47
Lateralization of ventral and dorsal auditory-language pathways in the human brain. Neuroimage (2004) 2.46
Evidence for acute neurotoxicity after chemotherapy. Ann Neurol (2010) 2.45
Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry (2010) 2.44
MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol (2006) 2.44
Genome-wide association studies of cerebral white matter lesion burden: the CHARGE consortium. Ann Neurol (2011) 2.37
Bleeding risk analysis in stroke imaging before thromboLysis (BRASIL): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients. Stroke (2007) 2.36
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain (2002) 2.30
White matter lesion progression, brain atrophy, and cognitive decline: the Austrian stroke prevention study. Ann Neurol (2005) 2.29
Neuroplasticity predicts outcome of optic neuritis independent of tissue damage. Ann Neurol (2010) 2.24
Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol (2009) 2.20
Magnetic resonance imaging pattern recognition in hypomyelinating disorders. Brain (2010) 2.19
Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. Neurology (2011) 2.17
Initial demonstration of in vivo tracing of axonal projections in the macaque brain and comparison with the human brain using diffusion tensor imaging and fast marching tractography. Neuroimage (2002) 2.14
A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry (2012) 2.13
Loss of 'small-world' networks in Alzheimer's disease: graph analysis of FMRI resting-state functional connectivity. PLoS One (2010) 2.12
Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol (2005) 2.10
Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler (2005) 2.10
MRI in multiple sclerosis: current status and future prospects. Lancet Neurol (2008) 2.08
Right-to-left shunt in CADASIL patients: prevalence and correlation with clinical and MRI findings. Stroke (2008) 2.07
Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol (2007) 2.07
Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol (2005) 2.07
Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler (2011) 2.07
Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med (2007) 2.06
Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol (2012) 2.05
Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. Lancet Neurol (2005) 2.01
Large-scale neuronal network dysfunction in relapsing-remitting multiple sclerosis. Neurology (2012) 2.00
MRI measures should be a primary outcome endpoint in Phase III randomized, controlled trials in multiple sclerosis: yes. Mult Scler (2014) 1.99
Grey matter pathology in multiple sclerosis. Lancet Neurol (2008) 1.97
Acute unilateral hearing loss as an early symptom of lateral cerebral sinus venous thrombosis. Arch Neurol (2012) 1.97
Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet (2004) 1.93
Higher risk of further vascular events among transient ischemic attack patients with diffusion-weighted imaging acute ischemic lesions. Stroke (2004) 1.91
Impact of white matter hyperintensities scoring method on correlations with clinical data: the LADIS study. Stroke (2006) 1.88
Age-related changes in grey and white matter structure throughout adulthood. Neuroimage (2010) 1.85
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol (2013) 1.84
Blood oxygenation level dependent contrast resting state networks are relevant to functional activity in the neocortical sensorimotor system. Exp Brain Res (2005) 1.84
Prediction of early neurological deterioration using diffusion- and perfusion-weighted imaging in hyperacute middle cerebral artery ischemic stroke. Stroke (2002) 1.80
Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study. Neuroradiology (2007) 1.80
Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol (2011) 1.79
Common variants at 12q14 and 12q24 are associated with hippocampal volume. Nat Genet (2012) 1.79
C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke (2003) 1.78
Imaging markers for Alzheimer disease: which vs how. Neurology (2013) 1.76
The relationship between diffuse axonal damage and fatigue in multiple sclerosis. Arch Neurol (2004) 1.76
Unusual variants of Alexander's disease. Ann Neurol (2005) 1.76
Investigating cervical spinal cord structure using axial diffusion tensor imaging. Neuroimage (2002) 1.76
On the etiology of incident brain lacunes: longitudinal observations from the LADIS study. Stroke (2008) 1.75
Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS. Mult Scler (2012) 1.75
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol (2016) 1.73
White matter damage in primary progressive aphasias: a diffusion tensor tractography study. Brain (2011) 1.73
Cognitive reserve and cortical atrophy in multiple sclerosis: a longitudinal study. Neurology (2013) 1.72
Risk for symptomatic intracerebral hemorrhage after thrombolysis assessed by diffusion-weighted magnetic resonance imaging. Ann Neurol (2008) 1.71
Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: application in multiple sclerosis. Neuroimage (2010) 1.71
Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol (2012) 1.70
Progression of cerebral white matter lesions: 6-year results of the Austrian Stroke Prevention Study. Lancet (2003) 1.70
Resting state fMRI in Alzheimer's disease: beyond the default mode network. Neurobiol Aging (2011) 1.70